Novel Anti-LY6G6D/CD3 T-Cell–Dependent Bispecific Antibody for the Treatment of Colorectal Cancer

New therapeutics and combination regimens have led to marked clinical improvements for the treatment of a subset of colorectal cancer. Immune checkpoint inhibitors have shown clinical efficacy in patients with mismatch-repair–deficient or microsatellite instability–high (MSI-H) metastatic colorectal...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Peiyin, Sun, Liping L., Clark, Robyn, Hristopoulos, Maria, Chiu, Cecilia P.C., Dillon, Michael, Lin, WeiYu, Lo, Amy A., Chalsani, Sreedevi, Das Thakur, Meghna, Zimmerman Savill, Kristin M., Rougé, Lionel, Lupardus, Patrick, Piskol, Robert, Husain, Bushra, Ellerman, Diego, Shivva, Vittal, Leong, Steven R., Ovacik, Meric, Totpal, Klara, Wu, Yan, Spiess, Christoph, Lee, Genee, Leipold, Douglas D., Polson, Andrew G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381132/
https://www.ncbi.nlm.nih.gov/pubmed/35364611
http://dx.doi.org/10.1158/1535-7163.MCT-21-0599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381132/
https://www.ncbi.nlm.nih.gov/pubmed/35364611
http://dx.doi.org/10.1158/1535-7163.MCT-21-0599

Ejemplares similares